The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as
compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week
treatment period in subjects with documented coronary artery disease.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators:
Bio-Inova Life Sciences International MDS Pharma Services